Ligand Binding Thermodynamics in Drug Discovery: Still a Hot Tip?
The use of ligand binding thermodynamics has been proposed as a potential success factor to accelerate drug discovery. However, despite the intuitive appeal of optimizing binding enthalpy, a number of factors complicate routine use of thermodynamic data. On a macroscopic level, a range of experimental parameters including temperature and buffer choice significantly influence the observed thermodynamic signatures. On a microscopic level, solute effects, structural flexibility, and cooperativity lead to nonlinear changes in enthalpy. This multifactorial character hides essential enthalpy contributions of intermolecular contacts, making them experimentally nonobservable. In this perspective, we present three case studies, reflect on some key factors affecting thermodynamic signatures, and investigate their relation to the hydrophobic effect, enthalpy-entropy compensation, lipophilic ligand efficiency, and promiscuity. The studies highlight that enthalpy and entropy cannot be used as direct end points but can together with calculations increase our understanding of ligand binding and identify interesting outliers that do not behave as expected.
Discovery Sciences, AstraZeneca R&D Mölndal , S-43183 Mölndal, Sweden.
Stefan
S
Geschwindner
CVMD Innovative Medicines, AstraZeneca R&D Mölndal , S-43183 Mölndal, Sweden.
Johan
J
Ulander
Discovery Sciences, AstraZeneca R&D Mölndal , S-43183 Mölndal, Sweden.
Patrik
P
Johansson
D000465:Algorithms; D000818:Animals; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D019277:Entropy; D006801:Humans; D008024:Ligands; D013816:Thermodynamics
D008024:Ligands